Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its holding in Protagonist Therapeutics (NASDAQ:PTGX) by 26.3% to 114,036 shares, valued at roughly $9.96 million (about 0.18% ownership).
• Analysts are broadly positive—13 analysts rate PTGX a Buy with an average price target of $108.15 and several recent target increases into the $100–125 range.
• Offsetting optimism, insiders have sold 213,486 shares (~$20.13 million) in the past 90 days, and the company recently missed quarterly expectations (EPS -$0.69 vs. -$0.53; revenue $7.44M vs. $14.92M).

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 26.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,036 shares of the company's stock after purchasing an additional 23,719 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.18% of Protagonist Therapeutics worth $9,960,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Farallon Capital Management LLC raised its position in shares of Protagonist Therapeutics by 0.4% during the 3rd quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company's stock valued at $411,601,000 after buying an additional 24,000 shares during the period. State Street Corp increased its stake in Protagonist Therapeutics by 18.5% during the second quarter. State Street Corp now owns 3,207,543 shares of the company's stock worth $177,281,000 after acquiring an additional 500,924 shares during the last quarter. Wellington Management Group LLP raised its position in Protagonist Therapeutics by 83.9% in the third quarter. Wellington Management Group LLP now owns 1,908,446 shares of the company's stock valued at $126,778,000 after purchasing an additional 870,708 shares during the period. Woodline Partners LP lifted its stake in shares of Protagonist Therapeutics by 51.9% in the 3rd quarter. Woodline Partners LP now owns 1,438,247 shares of the company's stock valued at $95,543,000 after purchasing an additional 491,363 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Protagonist Therapeutics by 218.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company's stock worth $60,369,000 after purchasing an additional 748,758 shares during the period. Hedge funds and other institutional investors own 98.63% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PTGX shares. HC Wainwright boosted their price objective on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a report on Friday, January 30th. Johnson Rice reissued a "buy" rating on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Truist Financial increased their price objective on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a "buy" rating in a research report on Tuesday, April 14th. TD Cowen boosted their target price on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. Finally, Citigroup upped their price target on Protagonist Therapeutics from $115.00 to $125.00 and gave the stock a "buy" rating in a research note on Thursday, March 19th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $108.15.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Lewis T. Williams sold 18,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total value of $1,483,560.00. Following the sale, the director owned 7,825 shares of the company's stock, valued at $644,936.50. This trade represents a 69.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William D. Waddill sold 20,000 shares of Protagonist Therapeutics stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the completion of the transaction, the director owned 7,825 shares of the company's stock, valued at $654,796. The trade was a 71.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 213,486 shares of company stock valued at $20,129,058 in the last 90 days. Insiders own 4.90% of the company's stock.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $100.00 on Monday. Protagonist Therapeutics, Inc. has a 52-week low of $41.28 and a 52-week high of $107.84. The firm has a market cap of $6.38 billion, a PE ratio of -48.78 and a beta of 2.12. The company's 50 day moving average is $97.15 and its two-hundred day moving average is $88.30.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The business had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. On average, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 1.02 earnings per share for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.